"Adenovirus Vector Technology: Next Generation Systems for Medical Therapy" (AD-VEC)

Baker, Andrew (Principal Investigator)

Deanery of Clinical Sciences

Status	Finished
Effective start/end date	1/10/15 → 28/02/17

Funding

EU government bodies: £237,485.00

1 Article
1 Review article

Human AdV-20-42-42, a promising novel adenoviral vector for gene therapy and vaccine product development
Ballmann, M. Z., Raus, S., Engelhart, R., Kaján, G. L., Beqqali, A., Hadoke, P. W., Van Der Zalm, C., Papp, T., John, L., Khan, S., Boedhoe, S., Danskog, K., Frängsmyr, L., Custers, J., Bakker, W. A. M., Van Der Schaar, H. M., Arnberg, N., Lemckert, A. A. C., Havenga, M. & Baker, A. H., 1 Sept 2021, (E-pub ahead of print) In: Journal of Virology.
Research output: Contribution to journal › Article › peer-review

Open Access
File
αvβ3 Integrin is Required for Efficient Infection of Epithelial Cells with Human 1 Adenovirus Type 26
Nestic, D., uil, T. G., Ma, J., Roy, S., Vellinga, J., Baker, A., Custers, J. & Majhen, D., 17 Oct 2018, In: Journal of Virology.
Research output: Contribution to journal › Review article › peer-review

Open Access
File